Efficacy of Oral Intake of Hydrogen-Rich Jelly Intake on Gingival Inflammation: A Double-Blind, Placebo-Controlled and Exploratory Randomized Clinical Trial
Maruyama T, Takayama E, Tokuno S, Morita M, Ekuni D. · Healthcare (Basel, Switzerland). 2025;13(5):577.
What kind of evidence is this?
Human
Human interventional or observational study
Cancer research
Other forms
Not reported in this record.
Not reported in this record.
Methods at a glance
Human participants studied for cancer research. See eligibility criteria in the linked full text.
Human study; the article does not state one consolidated sample total, so no total is inferred.
60 days
Full text reports an oral H₂-generating preparation. Detected intervention quantities or schedules: 40 ppm, 60 days.
an oral H₂-generating preparation — H₂ only unless the full text explicitly reports oxygen co-delivery.
H₂-related quantities reported in the intervention passages: 40 ppm, 60 days. Values are not combined across different experimental arms.
Not applicable — no inhaled H₂ intervention was identified in the full article.
No inhaled O₂ co-delivery was identified for this non-inhalation intervention.
Placebo or matched control reported in the full article.
Outcomes and reported result
tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers
Article-reported result excerpt (24 words maximum): “Conclusions : Administration of hydrogen-rich jelly for 14 days decreased gingival inflammation.” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Human evidence; design, sample size and comparator limit interpretation. Funding or grant information is reported in the full article. The full article contains a conflict, commercial-support or supplied-product declaration; consult the source wording.
Applies only to the population and protocol reported in this cancer research article.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 40077138 · DOI: 10.3390/healthcare13050577
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10